Can-Fite to Participate in Digital Bio-Europe Spring Partnering Conference ; Looks to Partner on Co-Development of Piclidenoson for Coronavirus Treatment  Meetings with prospective partners regarding Piclidenoson as a potential treatment for coronavirus , in addition to established indications for the Company 's drugs in Phase II and Phase III studies  PETACH TIKVA , Israel-- ( BUSINESS WIRE ) -- Can-Fite BioPharma Ltd .
( NYSE American:CANF ) ( TASE:CFBI ) , a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory , cancer and liver diseases , announced today that Dr .
Sari Fishman , the Company 's Director of Business Development , will participate in the digital Bio-Europe Spring partnering conference from March 23 to 27 , 2020 .
The conference , which had originally been scheduled for an in-person format in Paris , will now be conducted as the world 's largest fully digital life science partnering event .
In addition to conducting meetings regarding Can-Fite 's lead drug candidates , Piclidenoson and Namodenoson , for their established indications in Phase II and Phase III trials , Can-Fite has garnered interest from prospective partners for Piclidenoson as a potential treatment @ @ @ @ @ @ @ @ @ @ studies for the treatment of rheumatoid arthritis , has begun pre-clinical testing for the treatment of coronavirus .
Piclidenoson is an anti-rheumatic drug with positive efficacy signals in Phase II clinical studies and currently in Phase III .
The drug is also known to have anti-viral effects against single stranded RNA viruses .
Coronavirus is known to be a single stranded RNA virus .
Today , drugs with this profile are under clinical studies for the treatment of coronavirus to combat the uncontrolled immune response created by the disease .
China recently approved Roche 's Actemra , a rheumatoid arthritis drug , to treat coronavirus patients with lung damage .
In conjunction with Temple University 's Lewis Katz School of Medicine in Philadelphia , Can-Fite is currently testing Piclidenoson 's anti-viral effects against coronavirus .
Piclidenoson 's anti-viral properties are protected by U .
patent US7589075 .
" This is an important time for potential partner meetings , as we expect to announce our Phase II NASH results for Namodenoson by the end of March , and Piclidenoson is being evaluated as a potential treatment for coronavirus .
@ @ @ @ @ @ @ @ @ @ positive data , we intend to apply for a compassionate use program in Israel for Piclidenoson in the treatment of coronavirus , " stated Can-Fite CEO Dr .
Pnina Fishman .
Can-Fite 's drugs have an excellent safety profile , having treated more than 1,500 patients .
Namodenoson is currently being used to treat advanced liver cancer patients in Israel under a compassionate use program .
Approximately $18 million in upfront and milestone payments have been received to date by Can-Fite from out-licensing and distribution deals in certain countries located in Asia , Europe , and North America for indications including rheumatoid arthritis , psoriasis , liver cancer , and NASH .
Achieving future milestones may trigger additional milestone payments plus royalties .
About Can-Fite BioPharma Ltd .
Can-Fite BioPharma Ltd .
( NYSE American:CANF ) ( TASE:CFBI ) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer , inflammatory disease and sexual dysfunction .
The Company 's lead drug candidate , Piclidenoson , is currently in Phase III trials for @ @ @ @ @ @ @ @ @ @ , Namodenoson , recently completed a Phase II trial for hepatocellular carcinoma ( HCC ) , the most common form of liver cancer , and is in a Phase II trial for the treatment of non-alcoholic steatohepatitis ( NASH ) .
Namodenoson has been granted Orphan Drug Designation in the U .
and Europe and Fast Track Designation as a second line treatment for HCC by the U .
Food and Drug Administration .
Namodenoson has also shown proof of concept to potentially treat other cancers including colon , prostate , and melanoma .
CF602 , the Company 's third drug candidate , has shown efficacy in the treatment of erectile dysfunction .
These drugs have an excellent safety profile with experience in over 1,500 patients in clinical studies to date .
For more information please visit : www .
can-fite .
Forward-Looking Statements  This press release may contain forward-looking statements , about Can-Fite 's expectations , beliefs or intentions regarding , among other things , market risks and uncertainties , its product development efforts , business , financial condition , results of operations , strategies or prospects .
In addition , @ @ @ @ @ @ @ @ @ @ made or may make forward-looking statements , orally or in writing .
Forward-looking statements can be identified by the use of forward-looking words such as " believe , " " expect , " " intend , " " plan , " " may , " " should " or " anticipate " or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters .
These forward-looking statements may be included in , but are not limited to , various filings made by Can-Fite with the U .
Securities and Exchange Commission , press releases or oral statements made by or with the approval of one of Can-Fite 's authorized executive officers .
Forward-looking statements relate to anticipated or expected events , activities , trends or results as of the date they are made .
Because forward-looking statements relate to matters that have not yet occurred , these statements are inherently subject to risks and uncertainties that could cause Can-Fite 's actual results to differ materially from any future results expressed or implied by @ @ @ @ @ @ @ @ @ @ actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements .
Factors that could cause our actual results to differ materially from those expressed or implied in such forward-looking statements include , but are not limited to : our history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms , or at all ; uncertainties of cash flows and inability to meet working capital needs ; the initiation , timing , progress and results of our preclinical studies , clinical trials and other product candidate development efforts ; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials ; our receipt of regulatory approvals for our product candidates , and the timing of other regulatory filings and approvals ; the clinical development , commercialization and market acceptance of our product candidates ; our ability to establish and maintain strategic partnerships and other corporate collaborations ; the implementation of our business model and strategic plans for our business and product candidates ; @ @ @ @ @ @ @ @ @ @ maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others ; competitive companies , technologies and our industry ; statements as to the impact of the political and security situation in Israel on our business ; and risks and other risk factors detailed in Can-Fite 's filings with the SEC and in its periodic filings with the TASE .
In addition , Can-Fite operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control .
Can-Fite does not undertake any obligation to publicly update these forward-looking statements , whether as a result of new information , future events or otherwise .
Please note that once you make your selection , it will apply to all future visits to NASDAQ .
If , at any time , you are interested in reverting to our default settings , please select Default Setting above .
If you have any questions or encounter any issues in changing your default settings , please email isfeedback@nasdaq .
@ @ @ @ @ @ @ @ @ @ selected to change your default setting for the Quote Search .
This will now be your default target page ; unless you change your configuration again , or you delete your cookies .
Are you sure you want to change your settings ?  CLOSEX  Please disable your ad blocker ( or update your settings to ensure that javascript and cookies are enabled ) , so that we can continue to provide you with the first-rate market news and data you 've come to expect from us .
